AL
ALGEN.PA Genoway
- Market cap
- EUR 24.4M
- P/E
- -
- P/B
- 1.10x
- ROE
- -52.4%
- Dividend yield
- -
- Fundamental score
- 2.0/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ALGEN.PA undervalued?
Graham numberThe Graham number of Genoway cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genoway fundamental analysis
6 of 11 checks passedROE 1/2
The stock's ROE falls within an average range (5.04%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.
ROA 1/2
The stock's ROA (2.84%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.
PBV 2/2
The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.
DER 1/2
The stock has a reasonable amount of debt compared to its ownership (56%), suggesting a balanced financial position and a moderate level of risk.
Revenue Growth 1/2
With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity
Net Profit Growth 2/2
This company has consistently achieved strong net profit growth over the past five years, demonstrating a solid financial performance and making it an appealing investment option.
Assets Growth 0/2
Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.
Graham Number 0/1
The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.
Dividend Growth 0/2
The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.
Dividend 0/2
Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.
Buffet Intrinsic Value 0/1
The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Genoway stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genoway
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick K…
Full company profileGenoway financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genoway annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 11.5M | 13.2M | 15.0M | 14.3M | 11.0M | 14.0M | 17.1M | 20.0M | 22.1M | 21.0M | 33.7M |
| Gross Profit | 6.58M | 7.38M | 8.61M | 8.16M | -2.96M | -3.75M | -1.31M | 18.8M | -1.89M | 10.2M | -17.5M |
| Operating Income | 692K | 754K | 580K | -575K | -3.84M | -4.59M | 950K | 2.07M | 1.81M | 669K | -18.4M |
| EBITDA | 1.02M | 187K | -1.12M | 605K | -2.57M | -1.88M | 938K | 6.35M | 4.27M | 4.96M | -11.2M |
| Net Income | 582K | 1.93M | 572K | -1.04M | -687K | -323K | 778K | 1.57M | 1.83M | 928K | -11.4M |
| EPS | 0.10 | 0.32 | 0.10 | -0.18 | -0.10 | -0.04 | 0.09 | 0.17 | 0.19 | 0.07 | -0.93 |
| Balance Sheet | |||||||||||
| Total Assets | 11.7M | 17.2M | 19.7M | 19.2M | 27.6M | 32.5M | 32.9M | 31.8M | 31.8M | 45.4M | 45.6M |
| Total Liabilities | 6.44M | 9.98M | 11.8M | 12.3M | 18.6M | 17.9M | 16.8M | 14.5M | 13.2M | 20.4M | 23.8M |
| Shareholders' Equity | 5.26M | 7.19M | 7.89M | 6.84M | 9.00M | 14.7M | 16.2M | 17.4M | 18.6M | 25.0M | 21.8M |
| Cash & Short-term Investments | 2.64M | 3.95M | 3.05M | 1.09M | 2.72M | 5.61M | 4.88M | 4.26M | 4.95M | 7.05M | 3.30M |
| Total Debt | 10.7K | 4.18M | 4.67M | 6.02M | 10.8M | 10.8M | 9.05M | 7.23M | 5.58M | 13.8M | 15.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -902K | 621K | 847K | 1.18M | -164K | -561K | 2.36M | 3.06M | 5.38M | -1.43M | -7.41M |
| Capital Expenditure | 255K | 2.70M | 2.70M | 2.70M | 4.52M | 2.28M | 1.92M | 1.78M | 2.39M | 10.9M | 3.72M |
| Free Cash Flow | -1.16M | 621K | 847K | 1.18M | -4.68M | -2.84M | 439K | 1.28M | 2.99M | -12.4M | -11.1M |
| Ratios | |||||||||||
| ROE | 11.1% | 26.9% | 7.2% | -15.1% | -7.6% | -2.2% | 4.8% | 9.0% | 9.9% | 3.7% | -52.4% |
| ROA | 5.0% | 11.2% | 2.9% | -5.4% | -2.5% | -1.0% | 2.4% | 4.9% | 5.8% | 2.0% | -25.1% |
| Net Profit Margin | 5.0% | 14.7% | 3.8% | -7.3% | -6.2% | -2.3% | 4.6% | 7.8% | 8.3% | 4.4% | -34.0% |
| Debt to Equity | 0.00x | 0.58x | 0.59x | 0.88x | 1.20x | 0.74x | 0.56x | 0.42x | 0.30x | 0.55x | 0.70x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genoway dividends
Genoway has not paid dividends in the last 9 fiscal years.
Who owns Genoway
- Insiders 31.39%
- Institutions 13.81%
- Public & others 54.80%
- Shares outstanding 12.3M
Genoway company profile
- Company name
- Genoway
- Ticker
- ALGEN.PA
- ISIN
- FR0004053510
- Exchange
- Euronext Paris
- Listed since
- May 7, 2007
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- Technopark 2, Lyon, France, 69007
- Phone
- 33 4 37 65 41 00
- Website
- genoway.com
About Genoway
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and cell lines. It serves pharmaceutical and life science companies, and academic institutes. The company was incorporated in 1999 and is based in Lyon, France.
Genoway management
1- Dr. Alexandre FraichardFounder, GM & Director